Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.

about

Dasatinib-Induced Pulmonary Arterial Hypertension.

P2860

Q48243064-6A8AC54F-81D4-45E4-8360-F64EAFA129F5

P2860

Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.

Item

http://www.wikidata.org/entity/Q47975878

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Severe dyspnoea in a patient w ...... n a tyrosine kinase inhibitor.

@en

Severe dyspnoea in a patient w ...... n a tyrosine kinase inhibitor.

@nl

type

Item

label

Severe dyspnoea in a patient w ...... n a tyrosine kinase inhibitor.

@en

Severe dyspnoea in a patient w ...... n a tyrosine kinase inhibitor.

@nl

prefLabel

Severe dyspnoea in a patient w ...... n a tyrosine kinase inhibitor.

@en

Severe dyspnoea in a patient w ...... n a tyrosine kinase inhibitor.

@nl

P1476

Severe dyspnoea in a patient w ...... n a tyrosine kinase inhibitor.

@en

P2093

Celalettin Ustun

http://www.w3.org/2001/XMLSchema#string

Eitan Podgaetz

http://www.w3.org/2001/XMLSchema#string

H Erhan Dincer

http://www.w3.org/2001/XMLSchema#string

Khalid Amin

http://www.w3.org/2001/XMLSchema#string

Nicole Randall

http://www.w3.org/2001/XMLSchema#string

P2860

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.

Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.

Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature.

Comparison of early treatment with low doses of nilotinib, imatinib and a clinically relevant dose of silymarin in thioacetamide-induced liver fibrosis.

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.

Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: an insight.

Outcome of patients diagnosed with fibrinous pleuritis after medical thoracoscopy.

P304

701-704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/THORAXJNL-2015-206841

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25935168

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.

about

P2860

P2860

Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921